Create EXACTLY TWO 16:9 slides for a 5-minute MSc Clinical and Therapeutic Neuroscience research presentation at the University of Oxford. Use ONLY the uploaded dissertation for the study design, findings and interpretation. Do not invent data, statistics, methods, microscopy images or results. DESIGN STYLE This must look like a high-quality neuroscience conference presentation or scientific graphical abstract, NOT a corporate/business presentation. Prioritise scientific visuals over text: • ~80% visual, ~20% text • white/light background • restrained professional biomedical colour palette • substantial white space • large, readable typography • biological illustrations, arrows and simple experimental icons • maximum ~50 visible explanatory words per slide • NO paragraphs • NO numbered business-process boxes • NO large coloured rectangles • NO stock photographs • NO fake graphs or microscopy • NO generic decorative graphics The audience includes neuroscientists, psychiatrists, psychologists, neurologists and biomedical scientists, so make the biological rationale understandable without assuming specialist Parkinson’s disease knowledge. ──────────────────────────── SLIDE 1 TITLE: Can enhancing dopamine handling reduce neuronal vulnerability in Parkinson’s disease? PURPOSE: Explain the biological question and experimental strategy visually. LEFT ~50%: CREATE A LARGE BLANK PLACEHOLDER labelled: “INSERT MY DOPAMINE-HANDLING SCHEMATIC” Do NOT recreate the dopamine pathway because I will insert my own scientific illustration. Around/beside this figure, use only very short labels to communicate: Selective SNpc dopaminergic vulnerability ↓ Cytosolic dopamine as a candidate contributor Highlight the TWO complementary intervention points: VMAT2 “Vesicular sequestration” ALDH1A1 “DOPAL detoxification” Display ONE central research question prominently: “Can strengthening dopamine handling protect SNCA-triplication human dopaminergic neurons?” RIGHT ~50%: Create a compact ILLUSTRATED experimental workflow using cells, culture dishes and arrows—not text boxes. 3 healthy controls + 3 SNCA-triplication iPSC lines ↓ midbrain dopaminergic neurons ↓ three culture conditions: Untransduced | ALDH1A1 OE | VMAT2 OE ↓ four small visual assay icons: FFN206 Vesicular uptake nIRF Catechol oxidation CellROX ± rotenone Oxidative stress LIVE/DEAD + neurites Neuronal vulnerability Include the secondary objective as a SMALL side branch only: DANS + cortical + MSN triculture → ALDH1A1 marker validation Do not include differentiation details, assay concentrations, statistical methods or protocols. The viewer should understand Slide 1 primarily from the illustrations and arrows. ──────────────────────────── SLIDE 2 TITLE: Increasing dopamine-handling proteins was not sufficient for neuroprotection PURPOSE: Show my REAL DATA and then the mechanistic interpretation. Do NOT generate graphs or microscopy images. Make approximately 65–70% of the slide
Create EXACTLY TWO 16:9 slides for a 5-minute MSc Clinical and Therapeutic Neuroscience research presentation at the University of Oxford. Use ONLY the uploaded dissertation for the study design, findings and interpretation. Do not invent data, statistics, methods, microscopy images or results. DESIGN STYLE This must look like a high-quality neuroscience conference presentation or scientific graphical abstract, NOT a corporate/business presentation. Prioritise scientific visuals over text: • ~80% visual, ~20% text • white/light background • restrained professional biomedical colour palette • substantial white space • large, readable typography • biological illustrations, arrows and simple experimental icons • maximum ~50 visible explanatory words per slide • NO paragraphs • NO numbered business-process boxes • NO large coloured rectangles • NO stock photographs • NO fake graphs or microscopy • NO generic decorative graphics The audience includes neuroscientists, psychiatrists, psychologists, neurologists and biomedical scientists, so make the biological rationale understandable without assuming specialist Parkinson’s disease knowledge. ──────────────────────────── SLIDE 1 TITLE: Can enhancing dopamine handling reduce neuronal vulnerability in Parkinson’s disease? PURPOSE: Explain the biological question and experimental strategy visually. LEFT ~50%: CREATE A LARGE BLANK PLACEHOLDER labelled: “INSERT MY DOPAMINE-HANDLING SCHEMATIC” Do NOT recreate the dopamine pathway because I will insert my own scientific illustration. Around/beside this figure, use only very short labels to communicate: Selective SNpc dopaminergic vulnerability ↓ Cytosolic dopamine as a candidate contributor Highlight the TWO complementary intervention points: VMAT2 “Vesicular sequestration” ALDH1A1 “DOPAL detoxification” Display ONE central research question prominently: “Can strengthening dopamine handling protect SNCA-triplication human dopaminergic neurons?” RIGHT ~50%: Create a compact ILLUSTRATED experimental workflow using cells, culture dishes and arrows—not text boxes. 3 healthy controls + 3 SNCA-triplication iPSC lines ↓ midbrain dopaminergic neurons ↓ three culture conditions: Untransduced | ALDH1A1 OE | VMAT2 OE ↓ four small visual assay icons: FFN206 Vesicular uptake nIRF Catechol oxidation CellROX ± rotenone Oxidative stress LIVE/DEAD + neurites Neuronal vulnerability Include the secondary objective as a SMALL side branch only: DANS + cortical + MSN triculture → ALDH1A1 marker validation Do not include differentiation details, assay concentrations, statistical methods or protocols. The viewer should understand Slide 1 primarily from the illustrations and arrows. ──────────────────────────── SLIDE 2 TITLE: Increasing dopamine-handling proteins was not sufficient for neuroprotection PURPOSE: Show my REAL DATA and then the mechanistic interpretation. Do NOT generate graphs or microscopy images. Make approximately 65–70% of the slide
Created using ChatSlide
This presentation outlines a biological investigation into dopamine handling and its vulnerabilities. It begins by detailing the rationale behind targeting VMAT2 and ALDH1A1, alongside a visual workflow of iPSC-to-assay processes. The second slide presents real data from the dissertation, comparing control groups with ALDH1A1 and VMAT2 overexpression, assessing their impact on neuronal resilience. Finally, the closing takeaway succinctly states the neuroprotection conclusions, linking...